EUCTR2006-006149-15-IT进行中（未招募）不适用
An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients with Type 2 Diabetes - ND
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 53
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Presents with type 2 diabetes based on the disease diagnostic criteria
- •2.Have been exposed to exenatide for at least 3 months in previous Studies GWAO, GWAP, or GWAT.
- •3.Have interrupted their exenatide treatment for a period of 2 months to 2.5 years.
- •4.HbA1c of ≤10.5%.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
- •2.Are Lilly or Amylin employees.
- •3.Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
- •4.Have previously completed or withdrawn from this study.
- •5.Exclusion criterion [8] applies to females of child-bearing potential (not surgically sterilized and between menarche and 1 year postmenopause) only: Are breastfeeding, Test positive for pregnancy at the time of enrollment based on a blood serum pregnancy test, Intend to become pregnant during the study, Have not practiced a reliable method of birth control (for example, use of oral contraceptives or Norplant; diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices; partner with vasectomy; or abstinence) for 3 months prior to screening, Do not agree to continue to use a reliable method of birth control (see above) during the study, as determined by the investigator.
- •6.Has poorly controlled blood pressure (≥ 180 mm Hg, systolic value; ≥110 mm Hg, diastolic value).
- •7.Have a known allergy to exenatide.
- •8.Have taken marketed exenatide during the interim period between studies GWAO, GWAP, or GWAT and the current study.
- •9.Have a clinically significant coronary artery disease history or presence of Class III or IV cardiac disease, coronary artery bypass surgery, or angioplasty within the year prior to inclusion in the study; or is expected to require coronary artery bypass surgery or angioplasty during the course of the study.
- •10.Have a history of renal transplantation or are currently receiving renal dialysis or have an estimated creatinine clearance of <50 mL/min, as estimated by the Cockcroft-Gault equation.
- •11.Have obvious clinical signs or symptoms of liver disease, chronic hepatitis, or alanine aminotransaminase/serum glutamic pyruvic transaminase (ALT/SGPT) >2.5 times the upper limit of the reference range.
- •12.Used drugs for weight loss (for example, Xenical [orlistat], Meridia [sibutramine], Acutrim [phenylpropanolamine], Accomplia [rimonabant], or similar over-the-counter medications) within 3 months of screening.
- •13.Are currently treated with any of the following excluded medications: Drugs that directly affect gastrointestinal motility, including, but not limited to: Reglan (metoclopramide), Propulsid (cisapride), and chronic macrolide antibiotics.
- •14.Have an active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.
- •15.Have had an organ transplant.
- •16.Use insulin with daily dosage exceeding 1 U/kg.
研究者
相似试验
已完成
不适用
A prospective study for the effects of treatment with adalimumab in patients with psoriasis and psoriatic arthritisPsoriatic arthritis, psoriasisSkin and Connective Tissue DiseasesPsoriasisISRCTN23328456Academic Medical Center (AMC) (Netherlands)24
进行中（未招募）
不适用
Etude exploratoire de l’effet d’un traitement par acide nicotinique sur l’inflammation du tissu adipeux sous cutané - NIACINE 4processus de l'inflammation du tissu adipeux et des mécanismes de l'insulinorésistanceMedDRA version: 12.0Level: LLTClassification code 10029883Term: ObesityEUCTR2009-012124-85-FRCHU de Toulouse24
招募中
4 期
Treatment response and eating behavior patterns with GLP-1/GIP co-receptor agonistsDiabetes MellitusDiabetesJPRN-jRCT1041230070Yabe Daisuke90
已完成
不适用
A Randomised, Prospective Study of the Treatment of Superficial Partial-Thickness Burns:AWBAT (Trademark) vs. Biobrane (Registered Trademark)Superficial partial-thickness burnsSurgery - Other surgeryACTRN12609000765224Royal Adelaide Hospital60
招募中
1 期
Exploratory Clinical Study on the Effectiveness of Glycyrrhizin in Early Vascular Lesions of Systemic SclerosisSystemic SclerosisJPRN-UMIN000032238The University of Tokyo20